Imagine a world in which mental health treatments can be administered naturally and effectively. New approaches, new treatments, and new transformative ways of thinking are required – solutions where the world of healthcare and technology collide to help individuals and communities heal, discover meaning, and make deeper connections.
Imagine a world where there is a desire for greater wellness…for all.
Today, an increasing number of research scientists around the globe believe that psilocybin – the ingredient in magic mushrooms containing psychoactive indole alkaloids that produce the so-called psychedelic ‘trip’ when ingested – could be used to treat a wide variety of psychological conditions, ranging from depression to drug & alcohol dependency to eating disorders.
Numinus Wellness Inc. (NUMI) (TSX-V.NUMI, OTCMKTS: LKYSF, Forum) is a new Company that is advancing psychedelic laboratory testing, therapy, and research, with an ultimate purpose of delivering the highest quality outcomes to their clients – at their clinics and virtually – through safe, evidence-based psychedelic-assisted psychotherapies and other transformative and supportive health solutions.
The Company has created a unique ecosystem of health solutions centered around developing and supporting these therapies to treat a myriad of mental health ailments, primarily depression and substance use disorder. Numinus’s ecosystem units include Numinus Bioscience, Numinus R&D, and Numinus Health. Each unit is undertaking distinct, synergistic initiatives to hasten approved access to psychedelic-assisted psychotherapy models in Canada and position Numinus as a trusted industry leader for the eventual regulated rollout of these therapies once available.
The Compass Connection: “A Mushrooming Opportunity”
Big, smart money is now entering the psychedelic health & wellness space. In fact, a major announcement was just made on August 28th that may signal revolutionary changes to mainstreaming psilocybin treatment for mental health. Compass Pathways PLC – a U.K. unicorn start-up backed by tech billionaire Peter Thiel and lead investor Christian Angermayer – has recently filed to go public on the Nasdaq about four years after it was founded to explore the use of a psychedelic compound found in so-called magic mushrooms for treating depression. The Company’s first program is based on research into how psilocybin therapy could help people with treatment-resistant depression.
The initial funding round valued Compass at about USD$16 million, and the IPO will see the initial investors realizing a multiple of 10 times of their investment, “according to people familiar with the matter.”
To date, the company has raised US$116 million, according to data from Crunchbase Inc. This kind of money from progressive investors signals an optimism in the marketplace for psilocybin-centred companies.
In the News
Also signalling optimism in the market was the September 10th closing of Numinus’s own oversubscribed $4.6 million offering conducted by Mackie Research Capital Corp.
Founder, CEO, and Chair Payton Nyquvest commented on the raise:
“We are very pleased with the strong response leading to the oversubscribed close, particularly in this tough market environment. We would like to thank all our investors for placing their confidence in us. Our team is excited to accelerate the initiatives outlined in our prospectus as we believe our plans will ultimately deliver great value to not only those who are in such need of alternative transformative mental health solutions, but also to our shareholders.”
And recently, Numinus received Health Canada approval to amend the Company’s existing licence under the Controlled Drug and Substances Act to allow its researchers and scientists to conduct research to standardize the extraction of psilocybin from mushrooms. The amendment means Numinus is the first publicly traded company in Canada to be granted a licence by Health Canada to conduct research of this kind. The research will focus on “developing a proprietary extraction method from mushrooms to allow for consistent dosing and application of naturally produced psilocybin.”
Payton Nyquvest has this to say about the ground-breaking development:
“We are proud to be at the forefront of a new therapeutic category by advancing evidence-based science focused on wellness and personal connection at its core. Numinus is the only publicly traded company in Canada approved to develop a consistent psilocybin extraction method from naturally-produced mushrooms at a time when alternative therapeutic methods are increasingly being investigated and demand from clinical research is growing.”
With the Health Canada regulatory approval, Numinus will now be able to proceed with the production of naturally-sourced, sustainable psilocybin for research purposes and help fulfil the demand for an alternative to the synthetic option.
In further news, Numinus recently announced an innovative partnership with Together We Can Addiction Recovery and Education Society (TWC). The partnership will enable TWC to enhance its mental health and addiction recovery support services with tailored mind/body wellness programs. Numinus’s associated wellness clinic will benefit from the partnership with a dedicated stream of revenue, reinitiated since the clinic’s re-opening post-COVID earlier this month. This partnership propels the company further towards its purpose of providing the highest quality outcomes for clients at its clinics.
Today’s progressive-thinking investors are digging deeper into finding ethical companies that they not just feel good about investing in, but can profit from the long-term purpose and performance that these kinds of companies can provide. Today, the estimated annual economic burden of mental illness in Canada alone is $51 billion. The social and emotional costs in lives is even more staggering – 4,000 Canadians die by suicide per year – almost 11 suicides per day.
Numinus is a forward-thinking Company stepping up to the plate to battle the existential plague of mental illness and substance use disorder head on by developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted therapies.
For more information, visit numinus.ca.
FULL DISCLOSURE: This is a paid article produced by Stockhouse Publishing.